Novavax , best known these days for the NVX-CoV2373 coronavirus vaccine it’s developed, saw its shares rise by 1.5% on Monday, against a stock market that essentially traded sideways.
That move comes slightly over half a year after Novavax and SK bioscience started the rolling submission process to the Ministry.
Although NVX-CoV2373 still hasn’t been submitted for authorization by the FDA in the crucial U.S.
The news was tempered by the hard fact that Novavax would be far from a first mover in South Korea.